Literature DB >> 34321211

Regulation of telomere homeostasis and genomic stability in cancer by N 6-adenosine methylation (m6A).

Ji Hoon Lee1, Juyeong Hong1, Zhao Zhang1, Bárbara de la Peña Avalos2,3, Cecilia J Proietti4, Agustina Roldán Deamicis4, Pablo Guzmán G5, Hung-Ming Lam6, Jose Garcia6, Martine P Roudier6, Anthony E Sisk7, Richard De La Rosa1, Kevin Vu8, Mei Yang1, Yiji Liao1, Jessica Scheirer1, Douglas Pechacek1, Pooja Yadav9,10, Manjeet K Rao9,10, Siyuan Zheng10,11, Teresa L Johnson-Pais12, Robin J Leach3,9, Patricia V Elizalde4, Eloïse Dray2,3, Kexin Xu13.   

Abstract

The role of RNA methylation on N 6-adenosine (m6A) in cancer has been acknowledged, but the underlying mechanisms remain obscure. Here, we identified homeobox containing 1 (HMBOX1) as an authentic target mRNA of m6A machinery, which is highly methylated in malignant cells compared to the normal counterparts and subject to expedited degradation upon the modification. m6A-mediated down-regulation of HMBOX1 causes telomere dysfunction and inactivation of p53 signaling, which leads to chromosome abnormalities and aggressive phenotypes. CRISPR-based, m6A-editing tools further prove that the methyl groups on HMBOX1 per se contribute to the generation of altered cancer genome. In multiple types of human cancers, expression of the RNA methyltransferase METTL3 is negatively correlated with the telomere length but favorably with fractions of altered cancer genome, whereas HMBOX1 mRNA levels show the opposite patterns. Our work suggests that the cancer-driving genomic alterations may potentially be fixed by rectifying particular epitranscriptomic program.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Entities:  

Year:  2021        PMID: 34321211     DOI: 10.1126/sciadv.abg7073

Source DB:  PubMed          Journal:  Sci Adv        ISSN: 2375-2548            Impact factor:   14.136


  3 in total

Review 1.  Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.

Authors:  Fusheng Zhang; Haiyang Liu; Meiqi Duan; Guang Wang; Zhenghou Zhang; Yutian Wang; Yiping Qian; Zhi Yang; Xiaofeng Jiang
Journal:  J Hematol Oncol       Date:  2022-07-06       Impact factor: 23.168

Review 2.  The Basis and Promise of Programmable RNA Editing and Modification.

Authors:  Nicholas Lo; Xin Xu; Fraser Soares; Housheng Hansen He
Journal:  Front Genet       Date:  2022-01-28       Impact factor: 4.599

3.  ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators.

Authors:  Zhonglin Cai; Huan Xu; Gang Bai; Hanjing Hu; Di Wang; Hongjun Li; Zhong Wang
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.